Phase II trial of sorafenib in advanced thyroid cancer. - Wikidata - awgldk - TriplyDB

Phase II trial of sorafenib in advanced thyroid cancer.

Phase II trial of sorafenib in advanced thyroid cancer.

http://www.wikidata.org/entity/Q37121708

about

Angiogenesis-inhibitors for metastatic thyroid cancer Selective use of sorafenib in the treatment of thyroid cancer Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications Molecular Targeted Therapies of Aggressive Thyroid Cancer The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Sorafenib in metastatic thyroid cancer: a systematic review Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions Progress in molecular-based management of differentiated thyroid cancer Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Medical management of metastatic medullary thyroid cancer Current status and future perspectives in differentiated thyroid cancer Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer Loss of Rap1GAP in papillary thyroid cancer Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Hepatotoxicity of targeted therapy for cancer.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.Update: the status of clinical trials with kinase inhibitors in thyroid cancer Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer Current concepts and future directions in differentiated thyroid cancer.Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.Alternative medical treatment for radioiodine-refractory thyroid cancers.The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.Lessons from mouse models of thyroid cancer.Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer.A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr

P2860

Q24236743-DE271C00-C07D-4D30-9B87-DD4A8B40D090 Q26752891-7A0AF4EF-4414-45BD-BDF9-C1B8BF6EEB8A Q26764899-6F981CFB-4712-4B63-882C-C2BD82519A07 Q26774734-EE9BCB65-EC65-47C9-9503-B694E8388C9F Q26795503-E4293603-6616-49DF-84E5-C577ED7CA022 Q26821959-A85CA54C-205F-4CA8-B0A5-25A493B7931D Q26828884-F770F833-F785-4EFE-AACA-B418C58D86BC Q26862841-E1D2EB58-4E05-4A0F-B337-8F6823785BB3 Q26863326-3FD09EBE-C3D1-4F2D-BC2F-043FD7825305 Q26999887-59A422D4-4DBD-453A-8539-CA28DEE0E4BA Q27003304-3303599F-CF37-45D8-9188-C346D8235139 Q27005897-1AFB27E6-FD11-44EC-84AB-637382463FE1 Q27024484-3953021D-DCC8-4A21-9D90-5121B12B4AE3 Q27027491-E33D8068-72D4-4DDB-886B-EED1C3DD2574 Q27652488-ED6FB8B2-6DE1-4539-83E7-9477B11DEBAD Q27851560-9A0AB872-68E6-440F-9FBF-6AE0ECC22A7F Q28569254-AB276E4B-E2BD-4B00-88D2-D3150768DEDB Q30250273-C1E60BED-0D50-42E7-B132-330FC8092124 Q30250288-16AAF585-4C20-4A46-8DC3-2808C16C21EA Q30367068-03A463A9-DBA2-4683-A744-18DAFAB1AE93 Q30429122-48D14D66-9456-49EE-B0FE-ED593E857A6A Q31108636-E338BE96-A4EC-4FF8-AB72-7156CFD1ADDB Q33397349-00F636BB-41C9-49D7-9F62-E080E24AEB79 Q33404411-2D7F03BA-379C-4560-8E5D-4582B6D13D94 Q33514138-2A89DE9F-A9C5-4F04-B54E-0A35E86FD44D Q33570056-4990D1AA-3B57-47ED-A1F8-3863747BDF07 Q33577870-F3597171-99D0-4A73-8F2A-DE964A995B55 Q33582914-70F9635B-FFEC-4759-9472-E2DCBE067F5E Q33632654-E0DB4230-48E6-4F2A-8C37-1E2C9A5C1B5B Q33677589-DF28A59C-B839-44BA-8463-0482C37C78F5 Q33682381-0CB45C57-5099-4F3F-BE63-9420D935FF06 Q33704599-DE58E11D-1047-4C07-8732-FF81D884439A Q33770769-1995E1FC-2C71-494A-8B77-9B18DA97070D Q33819911-17953B41-0376-4D7A-B008-31E9473EB1D8 Q33927272-1DF56C4D-4F31-4033-A117-32C48F760702 Q33931434-B9F3558D-5DFA-4F75-936C-8A2A61F7D160 Q33931450-364B4CC7-4B14-464B-9884-097D7052AD0E Q33973831-C72B8EF5-5B4E-465A-9B21-F28AB329B558 Q33984845-49EE548E-F44B-4B4B-84AC-5C7F6F7FBA43 Q33990855-5E66A8E6-4076-4618-A1C1-333CE777EA94

P2860

Phase II trial of sorafenib in advanced thyroid cancer.

http://www.wikidata.org/entity/Q37121708

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 June 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II trial of sorafenib in advanced thyroid cancer.

@en

Phase II trial of sorafenib in advanced thyroid cancer.

@nl

type

label

Phase II trial of sorafenib in advanced thyroid cancer.

@en

Phase II trial of sorafenib in advanced thyroid cancer.

@nl

prefLabel

Phase II trial of sorafenib in advanced thyroid cancer.

@en

Phase II trial of sorafenib in advanced thyroid cancer.

@nl

P1433

Q37121708-C9CD9164-FC8D-46B6-8BB0-A70DFBDBC29B

P1476

Q37121708-924C8EEA-E187-444C-901F-0E57BE77EA3A

P2093

Q37121708-0D077EDD-609B-4241-AA19-7DFCE1DE9941

Q37121708-34806FA7-016D-4BB9-BB37-47898C3C2FA9

Q37121708-4F00B50D-B508-4EFF-9554-8B97B8190BED

Q37121708-6268C316-C8A9-46E4-852C-BFBD2A8DE083

Q37121708-748BE7DE-4668-42BF-90E7-0CA3A78A8FF2

Q37121708-7F96C1F0-D0B2-4230-9634-44D77A91F4A1

Q37121708-95B79404-8EAF-4923-BB00-84701EECBA0C

Q37121708-C7CAE24A-6348-41DD-9B19-7BC7AD9D5E8B

Q37121708-F3BDBC8F-4959-4865-B583-718C9EC4BBEB

P2860

Q37121708-0344AC49-96A6-441F-AE9B-1A924676F1A4

Q37121708-03E0F7D3-3E51-4964-8B05-1B5409089F36

Q37121708-0AFDDE15-7FFF-427B-8200-D4578898D906

Q37121708-1591CA11-A728-4DB2-973C-AC2675E5B775

Q37121708-31945BA6-CA96-40AE-8B57-82AA1574128C

Q37121708-37B01B22-C06D-4B53-A37A-99CE26F4C133

Q37121708-5B2EAC38-6D3A-48D4-AB1D-3FB366924B4E

Q37121708-603D1670-361C-4981-9F4C-21C211705C2A

Q37121708-607F2320-2041-46EE-8FB3-6622AE5BCFBC

Q37121708-64CBBFAD-C50A-4D9E-AB9F-280195FF7247

P304

Q37121708-75041D02-01D1-4981-AA45-56D2BF6A393B

P31

Q37121708-4BC925A0-CE8A-4E7A-8404-2226D421AF59

P356

Q37121708-2B471639-F6FD-4DDE-B4B4-56A5382FD070

P407

Q37121708-350A59EC-34EC-4CDF-985A-0C9FC589AF64

P433

Q37121708-07818F6B-C1CD-42E7-95A9-7B8D2B9F4775

P478

Q37121708-976889C5-182E-4E8B-A65E-4327A7AA6C51

P50

Q37121708-49F54BE4-56A1-451C-B882-DF605F17DFE7

Q37121708-F4BF4409-7F6C-4956-BE71-E207AB52485B

P577

Q37121708-C399929E-A440-4BD2-9A64-CBE824AFD455

P698

Q37121708-906084BA-C298-4C95-A62C-0B8768383983

P921

Q37121708-F5F4334D-3D7B-4CAF-B0EA-12B6424CA920

P932

Q37121708-CCA53216-AE3B-4F7C-A9D3-8B698B1E7606

P356

JCO.2008.16.3279

P1433

Journal of Clinical Oncology

P1476

Phase II trial of sorafenib in advanced thyroid cancer.

@en

P2093

Anoma Nellore

http://www.w3.org/2001/XMLSchema#string

Kanchan Puttaswamy

http://www.w3.org/2001/XMLSchema#string

Kathy Ransone

http://www.w3.org/2001/XMLSchema#string

Laurie A Loevner

http://www.w3.org/2001/XMLSchema#string

Marcia S Brose

http://www.w3.org/2001/XMLSchema#string

Maryann Redlinger

http://www.w3.org/2001/XMLSchema#string

Peter J O'Dwyer

http://www.w3.org/2001/XMLSchema#string

Susan J Mandel

http://www.w3.org/2001/XMLSchema#string

Vandana Gupta-Abramson

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of the BRAF gene in human cancer

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis

Sorafenib in advanced clear-cell renal-cell carcinoma

Cancer statistics, 2007

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma.

Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006)

BRAF mutation in thyroid cancer.

P304

4714-4719

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.16.3279

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Andrea B Troxel

P577

2008-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18541894

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2653134

http://www.w3.org/2001/XMLSchema#string